Longer‐term follow‐up and outcome by tumour cell proliferation rate (Ki‐67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL‐001(EMERGE) pivotal trial

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2141|170|4|496-503

ISSN： 0007-1048

Source： BRITISH JOURNAL OF HAEMATOLOGY, Vol.170, Iss.4, 2015-08, pp. : 496-503

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Prospective subgroup analyses of the randomized MCL‐002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 180, Iss. 2, 2018-01 ,pp. : 224-235

John Wiley & Sons Inc

Access to resources Recommend Favorite

Computerized image analysis of the Ki‐67 proliferation index in mantle cell lymphoma

By  

HISTOPATHOLOGY, Vol. 67, Iss. 1, 2015-07 ,pp. : 62-69

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase II trial of AZD1152 in relapsed/refractory diffuse large B‐cell lymphoma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 170, Iss. 6, 2015-09 ,pp. : 886-890

John Wiley & Sons Inc

Access to resources Recommend Favorite

Autologous stem cell transplantation with in vivo purged progenitor cells shows long‐term efficacy in relapsed/refractory follicular lymphoma

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 3, 2015-03 ,pp. : 230-234

John Wiley & Sons Inc

Access to resources Recommend Favorite

Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab

By  

CANCER, Vol. 119, Iss. 20, 2013-10 ,pp. : 3662-3671

John Wiley & Sons Inc

Access to resources Recommend Favorite